Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes

Circulation Journal

Volumn 71, Issue 1, 2007, Pages 144-152

  Chen, Yan ^a   Ohmori, Koji ^a   Mizukawa, Mizuki ^a   Yoshida, Junji ^a   Zeng, Yu ^a   Zhang, Ling ^a   Shinomiya, Kaori ^a   Kosaka, Hiroaki ^a   Kohno, Masakazu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Adiponectin; Diastolic dysfunction; Doppler echocardiography; Lipid lowering therapy; Nitric oxide

Indexed keywords

ADIPONECTIN; ATORVASTATIN; LEPTIN; PRAVASTATIN; TUMOR NECROSIS FACTOR;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE FAILURE; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RAT;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLUCOSE; HEPTANOIC ACIDS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LEPTIN; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PRAVASTATIN; PYRROLES; RATS; RATS, LONG-EVANS; RATS, MUTANT STRAINS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33845985670     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.144     Document Type: Article

References (41)

1. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: The strong heart study. Circulation 2000; 101: 2271-2276.
2. Hayden MR, Tyagi SC. Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit 2003; 9: SR35-SR52.
3. Kosuge M, Kimura K, Ishikawa T, Shimizi T, Hibi K, Toda N, et al. Persistent hyperglycemia is associated with left ventricular dysfunction in patients with acute myocardial infarction. Circ J 2005; 69: 23-28.
4. Yu Y, Ohmori K, Kondo I, Yao L, Noma T, Tsuji T, et al. Correlation of functional and structural alterations of the coronary arterioles during development of type II diabetes mellitus in rats. Cardiovasc Res 2002; 56: 303-311.
5. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899-907.
6. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.
7. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal. J Am Coll Cardiol 2004; 43: 2142-2146.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
9. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
10. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004; 291: 1071-1080.
11. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
12. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.
13. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005; 45: 1649-1653.
14. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CP. High Dose Atorvastatin Associated with Worse Glycemic Control: A PROVE-IT TIMI 22 Substudy (abstract). Circulation 2004; 110(Suppl): I-834.
15. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K, et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004; 44: 904-913.
16. Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: Results of the COMETS study. Eur Heart J 2005; 26: 2664-2672.
17. Wong V, Stavar L, Szeto L, Uffelman K, Wang CH, Fantus IG, et al. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006; 184: 348-355.
18. Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A. Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2006; 13: 95-100.
19. Ishikawa M, Namiki A, Kubota T, Yajima S, Fukazawa M, Moroi M, et al. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med 2006; 45: 51-55.
20. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): Implications in glycaemic control. Diabetologia 2006; 49: 1881-1889.
21. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41: 1422-1428.
22. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 2002; 16: 1163-1176.
23. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
24. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002; 99: 16309-16313.
25. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001; 89: 415-421.
26. Iwai H, Ohno Y, Aoki N. The effect of leptin, tumor necrosis factor-alpha (TNF-alpha), and nitric oxide (NO) production on insulin resistance in Otsuka Long-Evans fatty rats. Endocr J 2003; 50: 673-680.
27. Kosaka H, Yoneyama H, Zhang L, Fujii S, Yamamoto A, Igarashi J. Induction of LOX-1 and iNOS expressions by ischemia-reperfusion of rat kidney and the opposing effect of L-arginine. FASEB J 2003; 17: 636-643.
28. Altomonte J, Harbaran S, Richter A, Dong H. Fat depot-specific expression of adiponectin is impaired in Zucker fatty rats. Metabolism 2003; 52: 958-963.
29. Ranheim T, Haugen F, Staff AC, Braekke K, Harsem NK, Drevon CA. Adiponectin is reduced in gestational diabetes mellitus in normal weight women. Acta Obstet Gynecol Scand 2004; 83: 341-347.
30. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-24271.
31. Takayama T, Wada A, Tsutamoto T, Ohnishi M, Fujii M, Isono T, et al. Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J 2004; 68: 1067-1075.
32. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457.
33. Jesmin S, Sakuma I, Hattori Y, Fujii S, Kitabatake A. Long-acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodelling in a Type II diabetic rat model. Diabetologia 2002; 45: 402-415.
34. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-992.
35. Katusic ZS. Vascular endothelial dysfunction: Does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 2001; 281: H981-H986.
36. van Etten RW, de Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2002; 22: 799-804.
37. Monti LD, Barlassina C, Citterio L, Galluccio E, Berzuini C, Setola E, et al. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. Diabetes 2003; 52: 1270-1275.
38. Cook S, Hugli O, Egli M, Menard B, Thalmann S, Sartori C, et al. Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat diet-induced insulin resistance and arterial hypertension. Diabetes 2004; 53: 2067-2072.
39. Solomon SD, St John Sutton M, Lamas GA, Plappert T, Rouleau JL, Skali H, et al. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation 2002; 106: 1251-1255.
40. Kosuge M, Kimura K, Kojima S, Sakamoto T, Matsui K, Ishihara M, et al. Effects of glucose abnormalities on in-hospital outcome after coronary intervention for acute myocardial infarction. Circ J 2005; 69: 375-379.
41. Kosuge M, Kimura K, Ishikawa T, Shimizi T, Hibi K, Toda N, et al. Persistent hyperglycemia is associated with left ventricular dysfunction in patients with acute myocardial infarction. Circ J 2005; 69: 23-28.